Yokne’am-based Sofwave Medical (TASE: SOFW), which produces ultrasound programs for aesthetic therapies, has printed preliminary outcomes for the fourth quarter of 2025. Along with the outcomes, which point out continued development, the corporate introduced that it was inspecting the potential of an inventory on Nasdaq.
Sofwave was based by Dr. Shimon Eckhouse, who chairs the corporate and is a doyen of the Israeli aesthetic drugs business. He based Lumenis and Syneron, which established Israel’s prowess within the subject. He at the moment holds 24% of Sofwave.
The firm held an IPO on the Tel Aviv Stock Exchange in 2021, when it had but to make substantial gross sales. Since then it has made a profitable product launch, added new merchandise, and established itself within the aesthetic drugs market. Its present market cap is a few NIS 1 billion, after a 300% rise in its share worth from the low it reached eighteen months in the past.
According to the preliminary outcomes launched at present, fourth quarter income totaled $28.6-28.9 million, 57% greater than within the corresponding quarter of 2024. For 2025 as a complete the corporate expects to report income of $87.3-87.6, representing annual development of 46%. At the top of 2025, it had money and money equivalents amounting to $35.2 million, which compares with $26.5 million on the finish of 2024. In the primary 9 months of 2025, Sofwave switched to a revenue of $1.4 million, from a lack of $3.8 million within the corresponding interval of 2024.
Recognized within the US
The development in Sofwave’s gross sales prior to now 4 years and the extent they’ve reached make it an appropriate candidate for a Nasdaq providing. The model is thought within the US aesthetic drugs market, and the nice and cozy suggestion it obtained final yr from Kim Kardashian, who stated that it was “one of many solely therapies that truly companies the pores and skin,” will presumably do it no hurt.
Up to now, a lot of the aesthetic drugs corporations which have come out of Israel have reached the $100 million gross sales threshold and have then merged or been bought, and progressively ceased to be Israeli corporations. An exception is InMode (Nasdaq: INMD), based by Shimon Eckhouse’s former accomplice Moshe Mizrahy, which recorded gross sales of almost $400 million in 2024 however which, regardless of meteoric preliminary success, has skilled challenges prior to now two years in sustaining income ranges and has seen its share worth drop.
Eckhouse invests not simply in aesthetic drugs but in addition in medical gadget corporations. In 2021, he introduced Epitomee Medical (TASE: EPIT), developer of a capsule that expands within the abdomen for treating weight problems, to the Tel Aviv Stock Exchange.
This was a much less profitable flotation than that of Sofwave. Epitomee Medical is at the moment traded at 80% under its IPO valuation, with a market cap of simply NIS 200 million. The fall in its share worth was partly attributable to the cancelation of a distribution settlement signed with meals big Nestle. Epitomee Medical obtained advertising and marketing approval for its product within the US in September 2024, and it sees substantial gross sales solely in the direction of the top of this yr.
Published by Globes, Israel enterprise information – en.globes.co.il – on January 7, 2026.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2026.
